-
Which Strategy is More Effective in Patients with Rheumatoid Arthritis (RA) and Metotrexate Failure: Adding Leflunomide or TNFi?
Mar 10, 2025, 14:00 PM -
Characteristics and Adherence of Patients Initiating Injectable Cabotegravir for HIV Treatment or Prevention
Mar 10, 2025, 14:00 PM -
Health Equity and HTA: Is Equity Data Shaping Recommendations
Mar 10, 2025, 14:00 PM -
Why It Is Still Important to Ensure the Price is Right: Updates to Access Restrictions for Therapies Treating Duchenne Muscular Dystrophy
Mar 10, 2025, 14:00 PM -
Market Access Challenges for Innovative Medications in Women's Health in Canada: Overview of the Past 20 Years
Mar 10, 2025, 14:00 PM -
Prevalence of Claims-Reported Pruritus in Patients With Primary Biliary Cholangitis Overall and Among Those Treated With Obeticholic Acid
Mar 10, 2025, 14:00 PM -
Evaluating the Feasibility of a Network Meta-Analysis Comparing Treatment Options in Polycythemia Vera
Mar 10, 2025, 14:00 PM -
The Relationship Between Weight and Disease Severity in Dogs with Chronic Kidney Disease: Results from a Real-World Study
Mar 10, 2025, 14:00 PM -
Patient Value Assessment Using a Unified Measure Based on Data Envelopment Analysis: A Case Study
Mar 10, 2025, 14:00 PM -
Balancing Vulnerability and Freedom: Perspectives on HIV Cure-Related Trials With Analytical Treatment Interruption Among People With HIV and Healthcare Practitioners in the United States
Mar 10, 2025, 14:00 PM -
Is the IRA Drug Price Negotiation an Evidence-Based Practice? A Critical Analysis of the Evidence Reviewed by CMS for IRA Drug Price Negotiations and Implications for Future Submissions
Mar 10, 2025, 14:00 PM -
Mapping Disparities in Clinical Trial Enrollment Among HCC Patients: Insights From Social Determinants of Health
Mar 10, 2025, 14:00 PM -
The Use of Social Media Listening to Collect Oncology-Specific Patient Experience Data: A Scoping Review
Mar 10, 2025, 14:00 PM -
Insight into Approvals, Marketing, and Pricing of New Medicines 2018 to 2022
Mar 10, 2025, 14:00 PM -
Patient Characteristics Associated with the Use of Newly Approved Disease-Modifying Therapy (DMT) for Sickle Cell Disease in Texas Medicaid
Mar 10, 2025, 14:00 PM -
Estimating Healthcare Resource Utilization and Direct Costs of Chronic Myeloid Leukemia in the Brazilian Public Health System
Mar 10, 2025, 14:00 PM -
Development of New Patient Reported Outcome (PRO) Conceptual Models for Treatment Adherence and Satisfaction in People with HIV
Mar 10, 2025, 14:00 PM -
Patient- and Observer-Reported Outcomes with Therapeutic Medical Devices in Children and Adolescents with Obesity: A Systematic Literature Review
Mar 10, 2025, 14:00 PM -
Inclusion of Caregiver Costs and Quality of Life in Cost Effectiveness Analyses of Treatments for Neurological Conditions: Review of HTA Guidance Documents and Appraisals
Mar 10, 2025, 14:00 PM -
Racial and Ethnic Disparities in Healthcare Expenditures Among United States Older Adults with Joint Pain
Mar 10, 2025, 14:00 PM
